Title : Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.

Pub. Date : 2015 Dec 1

PMID : 26341687






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Studies have shown that the antidiabetic drug metformin could effectively increase the sensitivity of TKI-resistant lung cancer cells to EGFR-TKI. Metformin epidermal growth factor receptor Homo sapiens
2 Secondary data analysis showed that metformin use significantly prolonged the median PFS in subgroups using either first-line EGFR-TKI or second-line EGFR-TKI. Metformin epidermal growth factor receptor Homo sapiens
3 Secondary data analysis showed that metformin use significantly prolonged the median PFS in subgroups using either first-line EGFR-TKI or second-line EGFR-TKI. Metformin epidermal growth factor receptor Homo sapiens
4 CONCLUSIONS: Metformin and EGFR-TKI have a synergistic effect in the treatment of DM2 NSCLC patients harboring EGFR-activating mutations. Metformin epidermal growth factor receptor Homo sapiens
5 Metformin use is associated with improved survival and delayed onset of acquired resistance to EGFR-TKI. Metformin epidermal growth factor receptor Homo sapiens